Ambys Medicines

Big backing for venture capital-funded private biopharmaceutical companies has not wavered as 2021 draws to a close despite a recent slowdown in large initial public offerings by drug developers in th

US RNA interference specialist Arrowhead Pharmaceuticals, Inc. has now reached big pharma licensing deals for all three of its most advanced pipeline assets, this time striking an agreement with Ta

Third Rock Ventures LLC launched more than 50 biopharma, device and diagnostic companies with its first four venture capital funds, and with its fifth and largest – the $770m Third Rock Ventures V LP

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmace